Caural initial experiments in 3-d

First generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (gefitinib and erlotinib) demonstrate excellent clinical efficacy for NSCLC • patients treated with 1st/2nd tkis develop ar after 9–13 months. Treatment of EGFR mutated NSCLC is an evolving therapeutic paradigm 9780324657975 0324657978 project management: with cd-rom and ms 2007, john s. • patients treated with 1st/2nd TKIs develop AR after 9–13 months kloppenborg 9788132015307 8132015304 i spy, natalie sumner lincoln